Enpp-1-IN-2(Cat No.:I043459)is a selective inhibitor targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme involved in the regulation of extracellular nucleotides and mineralization. ENPP1 plays a crucial role in the hydrolysis of ATP and other nucleotides, influencing metabolic pathways and immune responses. By inhibiting ENPP1, Enpp-1-IN-2 aims to modulate these pathways, offering potential therapeutic benefits in conditions related to abnormal mineralization, such as cardiovascular disease, osteoporosis, and certain cancers. Ongoing research is focused on evaluating its efficacy, safety, and potential to treat diseases associated with ENPP1 dysfunction.